A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called ...

Most patients with metastatic prostate cancer receive drugs that block production of androgen, which promotes cancer cell proliferation. These drugs rarely actually cure cancer, however ...

The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis, as well as prognostic and predictive biomarkers, may further ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could unlock a sizeable new market for the drug.

Prostate cancer cells require large amounts of nutrients. When these run low, GCN2 signals the cells to produce more fuel.

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men With Biochemically Recurrent Prostate Cancer Aug. 22, 2024 — The anti-cancer drug olaparib may be effective in ...

Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not counteract that.

HRS-1167 is under clinical development by Merck and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).

The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.